We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+38.03%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$439M
AUM Growth
+$18.8M
Cap. Flow
-$56.2M
Cap. Flow %
-12.79%
Top 10 Hldgs %
79.78%
Holding
33
New
6
Increased
4
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$10.5M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.01M
3
CBAY
Cymabay Therapeutics
CBAY
+$3.98M
4
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$3.63M
5
KURA icon
Kura Oncology
KURA
+$2.92M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$24.1M
2
INCY icon
Incyte
INCY
+$12.6M
3
MDCO
Medicines Co
MDCO
+$11.6M
4
PTCT icon
PTC Therapeutics
PTCT
+$8.81M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$6.47M

Sector Composition

Rank Sector Weight
1 Healthcare 91.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$77.4M 17.62%
800,000
– –
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$62.1M 14.13%
600,000
– –
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$41.2M 9.38%
500,000
– –
MGNX icon
4
MacroGenics
MGNX
$235M
$40.7M 9.26%
2,200,000
+85,000
+4% +$1.47M
MDCO
5
DELISTED
Medicines Co
MDCO
$33.3M 7.59%
900,000
-315,000
-26% -$11.6M
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$25.1M 5.71%
500,000
-500,000
-50% -$24.1M
PTCT icon
7
PTC Therapeutics
PTCT
$5.64B
$25M 5.69%
1,250,000
-450,000
-26% -$8.81M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$17.4M 3.97%
250,000
– –
GTHX
9
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$15.7M 3.57%
629,179
– –
KURA icon
10
Kura Oncology
KURA
$800M
$12.6M 2.88%
844,789
+311,538
+58% +$2.92M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.1M 2.76%
1,037,994
– –
PBYI icon
12
Puma Biotechnology
PBYI
$404M
$12M 2.73%
100,000
– –
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
$9.3M 2.12%
267,500
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$8.16M 1.86%
1,012,986
+587,986
+138% +$3.98M
ZGNX
15
DELISTED
Zogenix, Inc.
ZGNX
$7.01M 1.6%
+200,000
New +$2.71M
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.22M 1.42%
+200,000
New +$6.01M
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.91M 1.35%
856,900
-83,100
-9% -$573K
ONCT
18
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$4.77M 1.09%
+4,038
New +$3.63M
NGNE icon
19
Neurogene
NGNE
$656M
$4.43M 1.01%
15,625
-10,625
-40% -$3.05M
SIOX
20
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.44M 0.78%
+62,500
New +$10.5M
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
$2.75M 0.63%
+18,315
New +$2.3M
BLPH
22
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.64M 0.6%
123,810
– –
ARDM
23
DELISTED
Aradigm Corp Common Stock
ARDM
$2.1M 0.48%
+500,000
New +$773K
VIRX
24
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.99M 0.45%
29,286
– –
VXX
25
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$1.96M 0.45%
50,000
-12,500
-20% -$580K
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Boxer Capital held 33 positions worth $439M, up 4.5% from $421M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Boxer Capital withdrew a net $56.2M in Q3 2017, closing 3 positions and reducing 9 holdings. Its most notable exit was Incyte, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 83% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Sio Gene Therapies Inc. Common Stock worth $3.44M.

  • Boxer Capital's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 62,500 shares worth $3.44M.
  • Boxer Capital added most to Cymabay Therapeutics in Q3 2017, an estimated $3.98M increase.
  • Boxer Capital's biggest Q3 2017 reduction was Esperion Therapeutics, cutting an estimated $24.1M.
  • Boxer Capital fully exited Incyte in Q3 2017, selling an estimated $12.6M.
  • Boxer Capital's ten largest holdings make up 80% of its $439M portfolio in Q3 2017.
  • Boxer Capital opened 6 new positions and closed 3 in Q3 2017.
  • Boxer Capital's portfolio value rose 4.5% quarter-over-quarter to $439M.

Based on Boxer Capital's 13F filing for Q3 2017, filed 14 Nov 2017.